PCSK9 inhibitors chosen as rapid uptake products by the AAC

The UK Secretary of State for Health and Social Care has announced that the PCSK9 inhibitor class has been selected as a treatment that needs to see a rapid increase in uptake to ensure that patients, and the National Health Service (NHS), get the benefits of this class of medicines.

Increasing the uptake of PCSK9 inhibitors in patients with high lipid levels, including those with primary familial hypercholesterolemia and mixed dyslipidemia who maybe at high-risk of cardiovascular disease may help reduce their low-density lipoprotein (LDL) concentrations towards recommended levels. Raised LDL levels are a risk factor for cardiovascular disease. The National Institute for Health and Care Excellence (NICE) believed there would be a relevant benefit both to patients and also to the NHS.

The Accelerated Access Collaborative (AAC) was announced in November 2017, following the government’s Accelerated Access Review (AAR), with the aim of getting breakthrough products to market, and then to patients, as quickly as possible.